Illinois Municipal Retirement Fund raised its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,996 shares of the medical research company’s stock after buying an additional 2,230 shares during the period. Illinois Municipal Retirement Fund’s holdings in Amgen were worth $25,710,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in AMGN. Rational Advisors Inc. increased its holdings in shares of Amgen by 13.7% during the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after buying an additional 24 shares in the last quarter. Beacon Financial Advisory LLC boosted its holdings in shares of Amgen by 2.0% in the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after acquiring an additional 25 shares in the last quarter. James T. Borello RIA boosted its holdings in shares of Amgen by 13.6% in the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after acquiring an additional 25 shares in the last quarter. Sweeney & Michel LLC boosted its holdings in shares of Amgen by 0.5% in the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after acquiring an additional 25 shares in the last quarter. Finally, Legacy Financial Advisors Inc. grew its position in Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after acquiring an additional 26 shares during the last quarter. 76.50% of the stock is owned by institutional investors.
Amgen News Summary
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
- Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
- Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article
Amgen Price Performance
Shares of AMGN stock opened at $465.23 on Wednesday. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The firm’s 50 day moving average is $423.79 and its 200-day moving average is $379.39. The firm has a market capitalization of $251.65 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 3.25 and a beta of 0.43.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same quarter last year, the business posted $5.64 earnings per share. Amgen’s revenue for the quarter was up 8.5% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 23.33 EPS for the current fiscal year.
Amgen Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is presently 58.47%.
Analysts Set New Price Targets
A number of research firms recently weighed in on AMGN. Piper Sandler raised their price target on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Scotiabank boosted their price objective on Amgen from $500.00 to $530.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, November 4th. Cantor Fitzgerald increased their target price on Amgen from $440.00 to $465.00 and gave the stock a “neutral” rating in a report on Wednesday, November 4th. Mizuho increased their target price on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. Finally, The Goldman Sachs Group raised their target price on Amgen from $481.00 to $536.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $422.76.
Check Out Our Latest Analysis on AMGN
Insider Buying and Selling
In other news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.
Amgen Company Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Articles
- Five stocks we like better than Amgen
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
